EBIO
Eleven Biotherapeutics, Inc.
Set alert
— — —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 9, 2018 | Laidlaw & Co. | init | — | Buy |
| Mar 19, 2018 | H.C. Wainwright | init | — | Buy |
| Jan 18, 2016 | Leerink Swann | down | — | Market Perform |
| Mar 2, 2014 | Citigroup | init | — | Buy |
| Mar 2, 2014 | Cowen & Co. | init | — | Outperform |
| Mar 2, 2014 | Citigroup | init | — | Buy |
News
- Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates
- Eleven Biotherapeutics to Report Third Quarter 2017 Financial Results on November 14, 2017
- Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017
- Eleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017
- Eleven Biotherapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Friday, March 24, 2017
- Eleven Biotherapeutics to Report Third Quarter 2016 Financial Results on November 14, 2016
- Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company
- Eleven Biotherapeutics to Report Third Quarter 2015 Financial Results on November 4, 2015
- Morning Market Gainers
- Eleven Biotherapeutics to Report Second Quarter 2015 Financial Results on August 13, 2015
Your note
Sign in to keep a note on EBIO — it syncs with the Stock Master app.